NYSE:RCUSBiotechs
Why Arcus Biosciences (RCUS) Is Down 15.4% After Ending Key Gastric Cancer Trial And Pivoting Pipeline
Arcus Biosciences and partner Gilead Sciences have discontinued the Phase 3 STAR-221 trial after an interim analysis showed domvanalimab plus zimberelimab and chemotherapy did not improve overall survival versus nivolumab plus chemotherapy in first-line advanced gastric and esophageal cancers, though safety remained comparable.
This setback is prompting Arcus to redirect development resources toward its HIF-2α inhibitor casdatifan and emerging small-molecule immunology and inflammation...